LP-6

• Description :

  LP-6 is a Drug-Linker Conjugate for ADC, and can be used for synthesis of ADCs. LP-6 consists of an Eg5 inhibitor and a linker[1].

• UNSPSC :

  12352203

• Target :

  Drug-Linker Conjugates for ADC; Kinesin

• Type :

  ADC Related

• Related Pathways :

  Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/lp-6.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CC([C@H](C1=NC(C2=CC(F)=CC=C2F)=CN1CC3=CC=CC=C3)N(C[C@H]4[C@H](CNC4)F)C([C@@H](O)C)=O)(CC(NCCN5C(C=CC5=O)=O)=O)C

• Molecular Formula :

  C36H41F3N6O5

• Molecular Weight :

  694.74

• References & Citations :

  [1]Karpov AS, et al. Discovery of Potent and Selective Antibody-Drug Conjugates with Eg5 Inhibitors through Linker and Payload Optimization. ACS Med Chem Lett. 2019 Dec 3;10 (12) :1674-1679.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  ADC Related

• Clinical Information :

  No Development Reported

• Isoform :

  Kinesin-5/Eg5/KSP

• CAS Number :

  [1629736-79-3]